Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Ref-1/APE1 inhibition with novel small molecules blocks ocular neovascularization.

Sardar Pasha SPB, Sishtla K, Sulaiman RS, Park B, Shetty T, Shah F, Fishel ML, Wikel JH, Kelley MR, Corson TW.

J Pharmacol Exp Ther. 2018 Aug 3. pii: jpet.118.248088. doi: 10.1124/jpet.118.248088. [Epub ahead of print]

2.

Presence of stromal cells in a bioengineered tumor microenvironment alters glioblastoma migration and response to STAT3 inhibition.

Herrera-Perez RM, Voytik-Harbin SL, Sarkaria JN, Pollok KE, Fishel ML, Rickus JL.

PLoS One. 2018 Mar 22;13(3):e0194183. doi: 10.1371/journal.pone.0194183. eCollection 2018.

3.

APE1/Ref-1 redox-specific inhibition decreases survivin protein levels and induces cell cycle arrest in prostate cancer cells.

McIlwain DW, Fishel ML, Boos A, Kelley MR, Jerde TJ.

Oncotarget. 2017 Dec 13;9(13):10962-10977. doi: 10.18632/oncotarget.23493. eCollection 2018 Feb 16.

4.

PTEN-Dependent Stabilization of MTSS1 Inhibits Metastatic Phenotype in Pancreatic Ductal Adenocarcinoma.

Zeleniak AE, Huang W, Fishel ML, Hill R.

Neoplasia. 2018 Jan;20(1):12-24. doi: 10.1016/j.neo.2017.10.004. Epub 2017 Nov 23.

5.

APE1/Ref-1 knockdown in pancreatic ductal adenocarcinoma - characterizing gene expression changes and identifying novel pathways using single-cell RNA sequencing.

Shah F, Goossens E, Atallah NM, Grimard M, Kelley MR, Fishel ML.

Mol Oncol. 2017 Dec;11(12):1711-1732. doi: 10.1002/1878-0261.12138. Epub 2017 Oct 19.

6.

Exploiting the Ref-1-APE1 node in cancer signaling and other diseases: from bench to clinic.

Shah F, Logsdon D, Messmann RA, Fehrenbacher JC, Fishel ML, Kelley MR.

NPJ Precis Oncol. 2017;1. pii: 19. doi: 10.1038/s41698-017-0023-0. Epub 2017 Jun 8.

7.

Ref-1/APE1 as a Transcriptional Regulator and Novel Therapeutic Target in Pediatric T-cell Leukemia.

Ding J, Fishel ML, Reed AM, McAdams E, Czader MB, Cardoso AA, Kelley MR.

Mol Cancer Ther. 2017 Jul;16(7):1401-1411. doi: 10.1158/1535-7163.MCT-17-0099. Epub 2017 Apr 26.

8.

Loss of MTSS1 results in increased metastatic potential in pancreatic cancer.

Zeleniak AE, Huang W, Brinkman MK, Fishel ML, Hill R.

Oncotarget. 2017 Mar 7;8(10):16473-16487. doi: 10.18632/oncotarget.14869.

9.

Regulation of HIF1α under Hypoxia by APE1/Ref-1 Impacts CA9 Expression: Dual Targeting in Patient-Derived 3D Pancreatic Cancer Models.

Logsdon DP, Grimard M, Luo M, Shahda S, Jiang Y, Tong Y, Yu Z, Zyromski N, Schipani E, Carta F, Supuran CT, Korc M, Ivan M, Kelley MR, Fishel ML.

Mol Cancer Ther. 2016 Nov;15(11):2722-2732. Epub 2016 Aug 17.

10.

Identification and Characterization of New Chemical Entities Targeting Apurinic/Apyrimidinic Endonuclease 1 for the Prevention of Chemotherapy-Induced Peripheral Neuropathy.

Kelley MR, Wikel JH, Guo C, Pollok KE, Bailey BJ, Wireman R, Fishel ML, Vasko MR.

J Pharmacol Exp Ther. 2016 Nov;359(2):300-309. Epub 2016 Sep 8.

11.

Cancer-associated fibroblast exosomes regulate survival and proliferation of pancreatic cancer cells.

Richards KE, Zeleniak AE, Fishel ML, Wu J, Littlepage LE, Hill R.

Oncogene. 2017 Mar 30;36(13):1770-1778. doi: 10.1038/onc.2016.353. Epub 2016 Sep 26.

12.

Applying Small Molecule Signal Transducer and Activator of Transcription-3 (STAT3) Protein Inhibitors as Pancreatic Cancer Therapeutics.

Arpin CC, Mac S, Jiang Y, Cheng H, Grimard M, Page BD, Kamocka MM, Haftchenary S, Su H, Ball DP, Rosa DA, Lai PS, Gómez-Biagi RF, Ali AM, Rana R, Hanenberg H, Kerman K, McElyea KC, Sandusky GE, Gunning PT, Fishel ML.

Mol Cancer Ther. 2016 May;15(5):794-805. doi: 10.1158/1535-7163.MCT-15-0003. Epub 2016 Feb 12.

13.

STAT3 in the systemic inflammation of cancer cachexia.

Zimmers TA, Fishel ML, Bonetto A.

Semin Cell Dev Biol. 2016 Jun;54:28-41. doi: 10.1016/j.semcdb.2016.02.009. Epub 2016 Feb 6. Review.

14.

Apurinic/apyrimidinic endonuclease/redox factor-1 (APE1/Ref-1) redox function negatively regulates NRF2.

Fishel ML, Wu X, Devlin CM, Logsdon DP, Jiang Y, Luo M, He Y, Yu Z, Tong Y, Lipking KP, Maitra A, Rajeshkumar NV, Scandura G, Kelley MR, Ivan M.

J Biol Chem. 2015 Jan 30;290(5):3057-68. doi: 10.1074/jbc.M114.621995. Epub 2014 Dec 9.

15.

Longitudinal Bioluminescence Imaging of Primary Versus Abdominal Metastatic Tumor Growth in Orthotopic Pancreatic Tumor Models in NSG Mice.

Shannon HE, Fishel ML, Xie J, Gu D, McCarthy BP, Riley AA, Sinn AL, Silver JM, Peterman K, Kelley MR, Hanenberg H, Korc M, Pollok KE, Territo PR.

Pancreas. 2015 Jan;44(1):64-75. doi: 10.1097/MPA.0000000000000238.

16.

Targeting DNA repair pathways for cancer treatment: what's new?

Kelley MR, Logsdon D, Fishel ML.

Future Oncol. 2014 May;10(7):1215-37. doi: 10.2217/fon.14.60. Review.

17.
18.

Selective ALDH3A1 inhibition by benzimidazole analogues increase mafosfamide sensitivity in cancer cells.

Parajuli B, Fishel ML, Hurley TD.

J Med Chem. 2014 Jan 23;57(2):449-61. doi: 10.1021/jm401508p. Epub 2014 Jan 10.

19.

APE1/Ref-1 regulates STAT3 transcriptional activity and APE1/Ref-1-STAT3 dual-targeting effectively inhibits pancreatic cancer cell survival.

Cardoso AA, Jiang Y, Luo M, Reed AM, Shahda S, He Y, Maitra A, Kelley MR, Fishel ML.

PLoS One. 2012;7(10):e47462. doi: 10.1371/journal.pone.0047462. Epub 2012 Oct 19.

20.
21.

Impact of APE1/Ref-1 redox inhibition on pancreatic tumor growth.

Fishel ML, Jiang Y, Rajeshkumar NV, Scandura G, Sinn AL, He Y, Shen C, Jones DR, Pollok KE, Ivan M, Maitra A, Kelley MR.

Mol Cancer Ther. 2011 Sep;10(9):1698-708. doi: 10.1158/1535-7163.MCT-11-0107. Epub 2011 Jun 23.

22.

Reduced expression of DNA repair and redox signaling protein APE1/Ref-1 impairs human pancreatic cancer cell survival, proliferation, and cell cycle progression.

Jiang Y, Zhou S, Sandusky GE, Kelley MR, Fishel ML.

Cancer Invest. 2010 Nov;28(9):885-95. doi: 10.3109/07357907.2010.512816.

23.

Inhibition of the redox function of APE1/Ref-1 in myeloid leukemia cell lines results in a hypersensitive response to retinoic acid-induced differentiation and apoptosis.

Fishel ML, Colvin ES, Luo M, Kelley MR, Robertson KA.

Exp Hematol. 2010 Dec;38(12):1178-88. doi: 10.1016/j.exphem.2010.08.011. Epub 2010 Sep 6.

24.

Novel small-molecule inhibitor of apurinic/apyrimidinic endonuclease 1 blocks proliferation and reduces viability of glioblastoma cells.

Bapat A, Glass LS, Luo M, Fishel ML, Long EC, Georgiadis MM, Kelley MR.

J Pharmacol Exp Ther. 2010 Sep 1;334(3):988-98. doi: 10.1124/jpet.110.169128. Epub 2010 May 26.

25.

Embryonic stem cells lacking the epigenetic regulator Cfp1 are hypersensitive to DNA-damaging agents and exhibit decreased Ape1/Ref-1 protein expression and endonuclease activity.

Tate CM, Fishel ML, Holleran JL, Egorin MJ, Skalnik DG.

DNA Repair (Amst). 2009 Dec 3;8(12):1411-23. doi: 10.1016/j.dnarep.2009.09.011. Epub 2009 Oct 15.

26.

Role of APE1 in differentiated neuroblastoma SH-SY5Y cells in response to oxidative stress: use of APE1 small molecule inhibitors to delineate APE1 functions.

Jiang Y, Guo C, Fishel ML, Wang ZY, Vasko MR, Kelley MR.

DNA Repair (Amst). 2009 Nov 2;8(11):1273-82. doi: 10.1016/j.dnarep.2009.08.003. Epub 2009 Sep 1.

27.
28.

Going ape as an approach to cancer therapeutics.

Bapat A, Fishel ML, Kelley MR.

Antioxid Redox Signal. 2009 Mar;11(3):651-68. doi: 10.1089/ARS.2008.2218. Review.

29.

Enhancement of cisplatin [cis-diammine dichloroplatinum (II)] cytotoxicity by O6-benzylguanine involves endoplasmic reticulum stress.

Rabik CA, Fishel ML, Holleran JL, Kasza K, Kelley MR, Egorin MJ, Dolan ME.

J Pharmacol Exp Ther. 2008 Nov;327(2):442-52. doi: 10.1124/jpet.108.141291. Epub 2008 Jul 29.

30.

DNA repair proteins as molecular targets for cancer therapeutics.

Kelley MR, Fishel ML.

Anticancer Agents Med Chem. 2008 May;8(4):417-25. Review.

31.

Knockdown of the DNA repair and redox signaling protein Ape1/Ref-1 blocks ovarian cancer cell and tumor growth.

Fishel ML, He Y, Reed AM, Chin-Sinex H, Hutchins GD, Mendonca MS, Kelley MR.

DNA Repair (Amst). 2008 Feb 1;7(2):177-86. Epub 2007 Oct 31.

32.

The DNA base excision repair protein Ape1/Ref-1 as a therapeutic and chemopreventive target.

Fishel ML, Kelley MR.

Mol Aspects Med. 2007 Jun-Aug;28(3-4):375-95. Epub 2007 May 3. Review.

PMID:
17560642
33.

Manipulation of base excision repair to sensitize ovarian cancer cells to alkylating agent temozolomide.

Fishel ML, He Y, Smith ML, Kelley MR.

Clin Cancer Res. 2007 Jan 1;13(1):260-7.

34.

DNA repair in neurons: so if they don't divide what's to repair?

Fishel ML, Vasko MR, Kelley MR.

Mutat Res. 2007 Jan 3;614(1-2):24-36. Epub 2006 Aug 1. Review.

PMID:
16879837
35.

Role of GADD34 in modulation of cisplatin cytotoxicity.

Fishel ML, Rabik CA, Bleibel WK, Li X, Moschel RC, Dolan ME.

Biochem Pharmacol. 2006 Jan 12;71(3):239-47. Epub 2005 Dec 1.

PMID:
16325149
36.

Role of glutathione and nucleotide excision repair in modulation of cisplatin activity with O6-benzylguanine.

Fishel ML, Gamcsik MP, Delaney SM, Zuhowski EG, Maher VM, Karrison T, Moschel RC, Egorin MJ, Dolan ME.

Cancer Chemother Pharmacol. 2005 Apr;55(4):333-342. doi: 10.1007/s00280-004-0901-3. Epub 2004 Oct 2.

PMID:
15723259
37.

Effect of cell cycle inhibition on Cisplatin-induced cytotoxicity.

Fishel ML, Newell DR, Griffin RJ, Davison R, Wang LZ, Curtin NJ, Zuhowski EG, Kasza K, Egorin MJ, Moschel RC, Dolan ME.

J Pharmacol Exp Ther. 2005 Jan;312(1):206-13. Epub 2004 Aug 10.

38.

Enhancement of platinum-induced cytotoxicity by O6-benzylguanine.

Fishel ML, Delaney SM, Friesen LD, Hansen RJ, Zuhowski EG, Moschel RC, Egorin MJ, Dolan ME.

Mol Cancer Ther. 2003 Jul;2(7):633-40.

40.

Implication of p53 in base excision DNA repair: in vivo evidence.

Seo YR, Fishel ML, Amundson S, Kelley MR, Smith ML.

Oncogene. 2002 Jan 24;21(5):731-7.

Supplemental Content

Loading ...
Support Center